Register
Login:
Share:
Email Facebook Twitter




Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 107.50Bid: 103.00Ask: 112.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 9.00Spread as %: 8.74%Open: 107.50High: 107.50Low: 107.50Yesterday’s Close: 107.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
107.50

Share Price SpacerBid
103.00

Share Price SpacerAsk
112.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
462

Share Price SpacerOpen
107.50

Share Price SpacerHigh
107.50

Share Price SpacerLow
107.50

Share Price SpacerClose
107.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.47m £66.08m 2,000

52 Week High 172.50 52 Week High Date 17-AUG-2015
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1 0 462 -3.707 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

30-Jun-16
12:56:40
111.49
462
Buy* 
103.00
112.00
515.08
Trade Type:
Ordinary

29-Jun-16
15:34:22
111.49
1,000
Buy* 
103.00
112.00
1,115
Trade Type:
Ordinary

29-Jun-16
13:46:05
111.11
21
Buy* 
103.00
112.00
23.33
Trade Type:
Ordinary



Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

30-Jun-16
12:56:40
111.49
462
Buy* 
103.00
112.00
515.08
Trade Type:
Ordinary



View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Wed 17:19AppleMacManRE: Action Duchenne News107.50No Opinion
FM .. a great introduction by Dame K to the science. I was busy when this happened on Wednesday and would recommend as FM suggests listening to Prof Kay's talk which explains what we are actually all here for. GLA.
Wed 16:20Free-MoneyRE: Action Duchenne News107.50No Opinion
They go into the differences between DMD and BMD in more detail in the New York conference, which you can listen to by the link on the company website.

http://edge.media-server.com/m/p/oow5xhwc

If you only have time to listen to Professor Davies then you should learn a lot of the detail, differences and hopes for the treatment.

Good luck to all the families involved.
Wed 16:10AppleMacManRE: Action Duchenne News107.50No Opinion
Great to see this also finds has some media coverage. I note that the end of the article specifically mentions the probability that Dame K's work will also help Becker muscular dystrophy ... which I've not realised effects the same number of patients as DMD.
Wed 14:06gmccRE: Action Duchenne News107.50No Opinion
HI EP Good find thanks got a mention on BBC !

http://www.bbc.co.uk/news/uk-england-oxfordshire-36639101

regards Gerry

ep
Wed 14:03Free-MoneyRE: JMP Securities 2016 Life Sciences107.50No Opinion
Thanks Gerry that was great to listen to. Great explanation of the trial and end points they hope to achieve. Key points I take is that they are confident Utrophin upregulation will work and they shown the distribution of Utrophin in animal models to be uniform through the fibre. Just need to show that in humans now. All very exciting.

And yes I completely agree that a deal (or deals) must be on the table for Ridinilazole and considering the outstanding results and benefits that deal should… Read More
Wed 13:17English_ParisienAction Duchenne News107.50No Opinion
http://www.actionduchenne.org/new-duchenne-muscular-dystrophy-treatment-ready-in-five-years/

"A new treatment for Duchenne muscular dystrophy could be available within five years.

Professor Kay Davies, an Oxford University researcher, has said trials of a drug to increase levels of the protein utrophin, to maintain the muscles, would start later this year and could help sufferers worldwide."

Follow the link from the Action Duchenne website for the full article
Bonne… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.






Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.